AI Article Synopsis
- Clonality levels of 25% or higher in patients are linked to a lower chance of achieving a very good partial response to ibrutinib treatment.
- *Patients with high clonality also experience shorter progression-free survival while on ibrutinib.
- *Assessing clonality can serve as a new biomarker to help predict treatment outcomes for patients with Waldenström macroglobulinemia using ibrutinib.
Article Abstract
clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784519 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2019000635 | DOI Listing |
Publication Analysis
Top Keywords
waldenström macroglobulinemia
8
clonality determinant
4
determinant ibrutinib
4
ibrutinib outcomes
4
outcomes patients
4
patients waldenström
4
macroglobulinemia clonality
4
clonality ≥25%
4
≥25% associated
4
associated lower
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!